(Adnkronos) - "I'm here at Gemelli, I say it smiling because I don't want to make it a tragic thing, for an operation". This is how the video shared on social media by Antonella Elia begins, as she ...
Icotyde's approval was significant for Johnson & Johnson because it introduced the first oral IL-23 receptor antagonist (a ...
A new commentary on efgartigimod in generalized myasthenia gravis warns that post-operative myasthenic crisis is too often ...
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment Optional ...
A retrospective study found that combining a thymoma with a three-millimeter rim of surrounding tissue on CT scans improved ...
JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges ...
FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk ...
Often considered an “expendable” organ in adulthood, the thymus is a small fatty gland in the lymphatic system, located ...
Johnson & Johnson (JNJ) is back in focus after new IMAAVY data in generalized myasthenia gravis, giving investors fresh insight into how its immunology pipeline might complement the stock’s recent ...
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By Nancy Lapid Oct 2 (Reuters) - Today we highlight a potentially unexpected ...
Background Efgartigimod, a neonatal Fc receptor (FcRn) blocker, effectively reduces total IgG, including pathogenic acetylcholine receptor (AChR) autoantibodies in myasthenia gravis (MG); however, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results